Swiss medtech firm Ypsomed has agreed to sell its diabetes business and insulin delivery technologies to TecMed for approximately $517.7 million.
The deal includes Ypsomed Diabetes Care’s subsidiaries and patch pump development activities, with the transaction expected to close in the second half of 2025. Ypsomed will shift its strategic focus toward subcutaneous self-injection markets following the sale.
TecMed plans to integrate Ypsomed’s mylife Loop system—including the mylife YpsoPump and the CamAPS FX automated insulin delivery solution—into its existing patch pump development program. According to Ypsomed, TecMed’s “clear vision in diabetes care” ensures stability and continuity for patients, employees, and partners throughout the transition.
This move marks a significant consolidation in diabetes management technologies, aligning two advanced insulin delivery portfolios under one organization.
Follow MEDWIRE.AI for more medical device industry updates.
